SignalSilence® Aldolase A siRNA I does not inhibit aldolase B or C expression.
Description
SignalSilence® Aldolase A siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit aldolase A expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
CST recommends transfection with 100 nM SignalSilence® Aldolase A siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Background
Aldolase (fructose bisphosphate aldolase), a glycolytic enzyme, catalyzes the conversion of fructose 1, 6-bisphosphate to 3-phosphoglyceraldehyde. This ubiquitous enzyme is present as three different isozymes: aldolase A, aldolase B, and aldolase C. Studies suggest the potential diagnostic value of quantitative analysis of aldolase A for hepatocarcinoma (1). Furthermore, the change in aldolase B gene expression levels has also been observed in certain patients with this primary tumor (2,3).